M4受体阻滞剂MT3抑制豚鼠形觉剥夺性近视的探讨

目的探讨高度选择性M4受体阻滞剂MT3对豚鼠形觉剥夺性近视的抑制作用及其潜在作用机理。方法 3周龄豚鼠随机分为三组:对照组、形觉剥夺组、形觉剥夺+MT3组。实验前后使用带状光检影测量屈光度,A超测量眼生物学参数,RT-PCR检测视网膜和脉络膜中TGF-β2的mRNA相对表达量。结果与对照组右眼相比,形觉剥夺+MT3组豚鼠右眼形成了(-1.44±0.50)D相对近视(右眼-左眼),玻璃体腔和眼轴长度分别延长(0.10±0.02)mm和(0.14±0.07)mm(P=0.001,P0.001,P0.001),但近视量、玻璃体腔和眼轴长度增加量均显著小于单纯形觉剥夺组(P0.001,P0.001,P0.001)。单纯形觉剥夺可引起视网膜和脉络膜TGF-β2的mRNA相对表达量下调(P0.001,P=0.014);而玻璃体腔注射MT3可导致形觉剥夺眼视网膜和脉络膜TGF-β2的mRNA相对表达量上调(P0.001,P0.001)。结论 MT3能抑制豚鼠形觉剥夺性近视的形成,其可能通过上调视网膜和脉络膜中TGF-β2的mRNA水平而发挥作用。     

玻璃体腔注射对裸小鼠视网膜组织形态学的影响

目的观察单纯的玻璃体腔注射对裸小鼠视网膜组织形态学的影响,为建立简单的制作视神经损伤动物模型奠定实验基础。方法在全身麻醉配合眼部局部麻醉情况下,利用微量注射器往裸小鼠玻璃体腔内迅速注入10μL生理盐水,然后在不同的时间点取注射眼进行固定、切片和HE染色,观察视网膜特别是视神经节细胞的变化。结果正常对照组视网膜层次清晰,各层排列整齐而致密,视网膜神经节细胞呈单层排列,大小不一,染色质分布均匀。实验组于注射后第1天、第3天和第5天视网膜神经节细胞减少的情况不明显,十层结构仍相对清晰。但于第7天,视网膜神经节细胞出现细胞明显缺失的现象,第14天为最严重,第30天和第60天与第14天相比无明显差别。结论玻璃体腔注射过量的生理盐水能够损伤视网膜组织,造成神经节细胞减少,有可能成为一种简单的制作视神经损伤动物模型的方法。     

骨髓基质干细胞移植改善慢性酒精中毒大鼠脑损害的相关机制研究

目的:探讨骨髓基质干细胞(bone marrow stormal cells, BMSCs)静脉移植对慢性酒精中毒大鼠脑保护作用的相关机制。方法:体外分离、培养、扩增SD大鼠BMSCs。成年雄性SD大鼠随机分为慢性酒精中毒组、BMSCs回输组、磷酸缓冲盐溶液(phosphate buffer saline,PBS)回输组和对照组,每组7只。前三组用酒精灌胃8周建立慢性酒精中毒动物模型,对照组不造模(给予蔗糖灌胃),BMSCs回输组和PBS回输组于造模7周时一次性经尾静脉回输BMSCs或PBS。免疫印迹法检测海马Bcl-2、Bax、NGF、BDNF以及信号转导分子p-Akt的表达;反转录PCR检测海马神经生长因子(nerve growth factor, NGF)和脑源性神经营养因子(brain derived neurotrophic factor, BDNF)。结果:BMSCs回输组海马抗凋亡蛋白Bcl-2表达高于其余三组(P0.05);促凋亡蛋白Bax表达低于慢性酒精中毒组(P0.01),与对照组无统计学差异(P=0.989)。BMSCs回输组鼠海马内NGF和BDNF m RNA和蛋白表达、p-Akt蛋白表达均高于其余三组(P0.05)。结论:静脉移植BMSCs能够明显改善慢性酒精中毒大鼠海马的细胞凋亡;其可能与自或旁分泌BDNF和NGF营养因子有关,且可能部分是通过激活PI3K/Akt通路实现。     

雷珠单抗联合复方血栓通与单独雷珠单抗治疗渗出老年性黄斑变性的前瞻性随机对照试验研究

目的:探讨复方血栓通(cFXST)对玻璃体腔注射雷珠单抗(IVR)治疗湿性老年性黄斑变性(wet-AMD)的辅助治疗作用。方法:纳入湿性老年性黄斑变性患者38例,以1:1的比例随机纳入Lucentis组(单独玻璃体腔注射雷珠单抗,19例)和cFXST组(玻璃体腔注射雷珠单抗联合复方血栓通,19例)。Lucentis组患者每月行玻璃体腔注射雷珠单抗(IVR),共计3次;cFXST组患者除IVR外,每日口服cFXST。分别在基线、玻璃体腔注射Lucentis后1个月、3个月记录最佳矫正视力(BCVA)和光学相干断层扫描(OCT)影像上视网膜新生血干至色素上皮下厚度(CNV-PED)。结果:cFXST组CNV-PED厚度在1月和3月分别降低31.7%和36.1%,高于Lucentis组的19.7%(P=0.021)、24.2%(P=0.018)。3个月后,cFXST组BCVA变化(P=0.045)及视力提高显著的患者比例(16/16 vs 8/17,P=0.001)明显高于Lucentis组。结论:每日口服cFXST治疗可提高抗VEGF治疗老年wet-AMD的短期疗效。     

BMSCs 选择性迁移对大鼠全脑缺血模型认知功能的影响

目的:探究不同时间点移植后骨髓间充质干细胞(BMSCs)的选择性迁移对大鼠全脑缺血/再灌注模型认知功能的影响以及可能的分子机制。方法:成年雄性SD大鼠80只,随机分为四组,全脑缺血再灌注组(model组,n=20),假手术组(sham组,n=20),造模1 d后较早BMSCs移植组(early组,n=20),造模7 d后较晚移植组(late组,n=20)。结扎双侧颈总动脉并结合低血压建立大鼠全脑缺血/再灌注模型,后于不同时间点尾静脉移植GFP+BMSCs。造模后1、3、7、14 d用酶联免疫法(ELISA)检测模型损伤区域大鼠皮层和海马部位的SDF-1α和MCP-1的表达水平,28 d后进行Morris水迷宫检测认知改变,32 d通过免疫组织化学染色和Western blot观察GFP+BMSCs的分布情况。结果:水迷宫实验表明细胞移植组相比sham组参数有显著提升,且early组相比late组表现更好(P0.05);GFP免疫组化和western结果表明,early组BMSCs移植后分布于海马更多(P0.05),而late组中BMSCs在皮层分布更多(P0.05);ELISA结果表明,造模后1 d模型大鼠海马区域的SDF-1α和MCP-1的表达水平呈现短暂的相对性上调(P0.05),而造模7 d后相关皮层区域的SDF-1α表达缓慢上调(P0.05)。结论:造模后早期(1 d)移植BMSCs比晚期能更好的改善模型大鼠的认知功能;造模后SDF-1α和MCP-1的时空变化可能介导了BMSCs的选择行迁移,后者直接决定了对模型大鼠的认知功能改善的疗效。     

骨髓间充质干细胞移植对急性脊髓损伤脱髓鞘病变的保护作用

骨髓间充质干细胞(Bone marrow mesenchymal stem cells,BMSCs)已被广泛应用于治疗脊髓损伤,但目前对其治疗机制了解甚少。BMSCs被移植至脊髓钳夹损伤模型大鼠,以研究其保护作用。通过LFB(Luxol fast blue)染色、锇酸染色、TUNEL(Td T-mediated d UTP nick-end labeling)染色和透射电镜对白质有髓神经纤维进行观察。免疫印迹检测BMSCs移植对脑源性神经营养因子(Brain derived neurotrophic factor,BDNF)和caspase 3蛋白表达的影响。通过脊髓损伤后1、7、14 d三个时间点移植BMSCs并进行后肢运动评分(Basso,beattie and bresnahan;BBB评分)和CNPase(2′,3′-cyclic-nucleotide 3′-phosphodiesterase)、髓鞘碱性蛋白(Myelin basic protein,MBP)、caspase 3蛋白水平的检测。免疫荧光观察BMSCs移植到受损脊髓后分化情况及CNPase-caspase 3~+共表达情况。骨髓间充质干细胞移植7 d后,部分移植的BMSCs可表达神经元和少突胶质细胞标记物,大鼠后肢运动能力和髓鞘超微结构特征均明显改善。骨髓间充质干细胞移植后BDNF蛋白表达水平增加,caspase 3蛋白表达水平则降低。相对于脊髓损伤后1 d和14 d,7 d移植BMSCs后MBP和CNPase蛋白表达水平最高;caspase 3蛋白表达水平则最低。骨髓间充质干细胞移植后CNPase-caspase 3~+细胞散在分布于脊髓白质。结果表明,急性脊髓损伤后,BMSCs移植到受损脊髓有分化为神经元和少突胶质细胞的倾向,并促进BDNF的分泌介导抗少突胶质细胞凋亡而对神经脱髓鞘病变有保护作用,且最佳移植时间为脊髓损伤后7 d。     

胸腺内注射供体BMSCs对同种异体腹部皮瓣移植排斥的影响

目的:将供体骨髓间充质干细胞(bone marrow mesenchymal stem cells,BMSCs)胸腺内注射(intrathymic injection,IT)至受体胸腺,探讨其对同种异体腹部皮瓣移植排斥的影响及机制。方法:全骨髓贴壁培养法培养并纯化BN大鼠BMSCs,流式细胞术对其表型进行鉴定。受体Lewis鼠随机分为A组(空白对照组)、B组(BMSCs组)、C组(60Coγ射线4Gy全身照射组)、D组(全身照射+BMSCs组),每组6只。各组大鼠第0天进行同种异体腹部皮瓣移植,A组移植前14天IT PBS,B组移植前14天IT供体BMSCs,C组移植前15天给予60Coγ射线4Gy全身照射,移植前14天IT PBS,D组除移植前15天4Gy全身照射外,移植前14天IT供体BMSCs。大体观察移植皮瓣存活情况并绘制生存曲线,排斥终点流式检测脾细胞调节性T细胞(Treg)比例变化,体外混合淋巴细胞反应检测受体脾淋巴细胞对供体抗原反应性变化。结果:全骨髓贴壁培养法能够很好培养出BMSCs,其P3代流式细胞术表型鉴定结果为CD11b/c、CD45阴性,CD29、CD90阳性。B组的移植皮瓣存活时间与A组相比无明显差异(P>0.05),而D组的移植皮瓣平均存活时间较C组延长3.4天,差异具有统计学意义(P<0.01),脾细胞Treg比例显著增高(P<0.01),脾淋巴细胞对供体抗原反应性显著降低(P<0.05)。结论:IT供体BMSCs联合60Coγ射线4Gy全身照射通过上调受体脾细胞Treg比例能有效降低受体脾淋巴细胞对供体抗原的反应性,显著延长同种异体腹部皮瓣移植物存活时间。     

北京鸭视网膜节细胞的大小、密度和分布

采用Nissl染色法、视神经溃变法和神经元逆行追踪标记辣根过氧化物酶(HRP)法,研究了北京鸭视网膜节细胞(RGCs)的大小和密度及其分布的变化。北京鸭RGCs形态多样,有圆形、椭圆形和多角形等,RGCs总数为1.3×106个(P0),RGCs平均密度为5370个/mm2(P0),在视网膜中央有一个偏向鼻侧的高密度区即中央高密度区(8860个/mm2),由中央区至周边部,细胞密度逐渐降低,颞侧周边部最低(3440个/mm2)。不同区域RGCs大小差异显著,中央区以小细胞为主(62.2±23.3μm2,P0),而周边部RGCs逐渐增大,颞侧周边部最大(P0:133.7±75.7μm2;P8:152.9±55.9μm2)。由此可见,伴随RGCs大小由中央区至周边部的递增而细胞密度呈现递减的变化,这种变化趋势在颞侧周边部最明显。与此同时,随日龄增长,RGCs总数和密度均递减而细胞大小递增。dACs是位于视网膜节细胞层的小神经元,细胞大小为23.7±4.0μm2     

雷珠单抗与阿柏西普玻璃体腔注射治疗渗出性年龄相关性黄斑变性的疗效观察

目的:探究雷珠单抗与阿柏西普玻璃体腔注射治疗渗出性年龄相关性黄斑变性的临床疗效与安全性。方法:选取2015年5月～2018年5月我院收治的渗出性年龄相关性黄斑变性患者98例(98眼),采用随机数字表法将患者分为两组,A组玻璃体腔内缓慢注射0.05 m L(0.5 mg)雷珠单抗注射液,B组玻璃体腔内缓慢注射0.05 m L(2 mg)阿柏西普注射液。比较两组患者的视力改善情况、眼动脉血流动力学、黄斑中心凹视网膜厚度及不良反应的发生情况。结果:治疗前两组患者的视力比较无统计学差异(P0.05),治疗后,B组视力显著高于A组(P0.05);。两组患者治疗前后眼动脉血流动力学相关指标比较均无统计学差异(P0.05)。;两组患者治疗后的黄斑中心凹视网膜厚度均显著降低,且治疗3个月B组治疗3个月显著低于A组(P0.05);B组患者注射药物后结膜下大出血发生率显著低于A组(P0.05)。结论:阿柏西普可显著改善渗出性年龄相关性黄斑变性患者的视力,且安全性高,可能与其可显著改善患者的黄斑中心凹视网膜厚度有关,且不良反应发生率低,安全性好。     

豚鼠眼形觉剥夺后恢复期的生物学参数变化规律探讨

目的探讨豚鼠眼球形觉剥夺后恢复期的生物学参数变化规律。方法普通级2～3周龄豚鼠30只,随机分为两组：①实验组：20只,右眼采用半透明眼罩遮盖进行形觉剥夺4周,随后去遮盖3周,左眼作为自身对照;②正常对照组：10只,双眼不进行任何干预,开放饲养7周。形觉剥夺前、形觉剥夺4周后及去遮盖后第2、6、10、14和21天,测量豚鼠双眼生物学参数：睫状肌麻痹后行带状光检影测量屈光度;A超测量前房深度、晶体厚度和眼轴长度,计算出玻璃体腔长度。结果经过4周形觉剥夺,实验组豚鼠右眼向近视漂移,屈光度为（-2.88±2.30）D,诱导了（-5.50±1.9）D相对近视。去遮盖后,豚鼠右眼重新正视化,屈光度恢复的快速期发生在6 d内,14 d时双眼屈光度差值差异无显著性（t=-2.049,P=0.080）,为（-0.18±0.26）D;右眼玻璃体腔长度缩短,14 d时双眼玻璃体腔长度差值差异无显著性（t=1.652,P=0.14）,为（0.0234±0.0400）mm;右眼眼轴长度缩短,14 d时双眼眼轴长度差值差差异无显著性（t=1.443,P=0.192）,为（0.0183±0.0359）mm。与正常对照组右眼相比,去遮盖6 d,屈光度差异为（-0.48±0.36）D,差异无显著性（t=-1.325,P=0.206）,而2 d时玻璃体腔和眼轴长度差异分别为（0.0961±0.0630）mm、（0.0621±0.0386）mm,差异无显著性（t=1.652,P=0.14;t=1.607,P=0.125）。结论 2～3周龄豚鼠去除形觉剥夺后可以重新进行正视化,伴随玻璃体腔和眼轴长度缩短;去遮盖6 d内为眼生物学参数恢复的主要时期。     

Positive Effects of bFGF Modified Rat Amniotic Epithelial Cells Transplantation on Transected Rat Optic Nerve

PurposeEffective therapy for visual loss caused by optic nerve injury or diseases has not been achieved even though the optic nerve has the regeneration potential after injury. This study was designed to modify amniotic epithelial cells (AECs) with basic fibroblast growth factor (bFGF) gene, preliminarily investigating its effect on transected optic nerve.MethodsA human bFGF gene segment was delivered into rat AECs (AECs/hbFGF) by lentiviral vector, and the gene expression was examined by RT-PCR and ELISA. The AECs/hbFGF and untransfected rat AECs were transplanted into the transected site of the rat optic nerve. At 28 days post transplantation, the survival and migration of the transplanted cells was observed by tracking labeled cells; meanwhile retinal ganglion cells (RGCs) were observed and counted by employing biotin dextran amine (BDA) and Nissl staining. Furthermore, the expression of growth associated protein 43 (GAP-43) within the injury site was examined with immunohistochemical staining.ResultsThe AECs/hbFGF was proven to express bFGF gene and secrete bFGF peptide. Both AECs/hbFGF and AECs could survive and migrate after transplantation. RGCs counting implicated that RGCs numbers of the cell transplantation groups were significantly higher than that of the control group, and the AECs/hbFGF group was significantly higher than that of the AECs group. Moreover GAP-43 integral optical density value in the control group was significantly lower than that of the cell transplantation groups, and the value in the AECs/hbFGF group was significantly higher than that of the AECs group.ConclusionsAECs modified with bFGF could reduce RGCs loss and promote expression of GAP-43 in the rat optic nerve transected model, facilitating the process of neural restoration following injury.     

Engrafted Human Induced Pluripotent Stem Cell-Derived Anterior Specified Neural Progenitors Protect the Rat Crushed Optic Nerve

Background

Degeneration of retinal ganglion cells (RGCs) is a common occurrence in several eye diseases. This study examined the functional improvement and protection of host RGCs in addition to the survival, integration and neuronal differentiation capabilities of anterior specified neural progenitors (NPs) following intravitreal transplantation.

Methodology/Principal Findings

NPs were produced under defined conditions from human induced pluripotent stem cells (hiPSCs) and transplanted into rats whose optic nerves have been crushed (ONC). hiPSCs were induced to differentiate into anterior specified NPs by the use of Noggin and retinoic acid. The hiPSC-NPs were labeled by green fluorescent protein or a fluorescent tracer 1,1′ -dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI) and injected two days after induction of ONC in hooded rats. Functional analysis according to visual evoked potential recordings showed significant amplitude recovery in animals transplanted with hiPSC-NPs. Retrograde labeling by an intra-collicular DiI injection showed significantly higher numbers of RGCs and spared axons in ONC rats treated with hiPSC-NPs or their conditioned medium (CM). The analysis of CM of hiPSC-NPs showed the secretion of ciliary neurotrophic factor, basic fibroblast growth factor, and insulin-like growth factor. Optic nerve of cell transplanted groups also had increased GAP43 immunoreactivity and myelin staining by FluoroMyelin™ which imply for protection of axons and myelin. At 60 days post-transplantation hiPSC-NPs were integrated into the ganglion cell layer of the retina and expressed neuronal markers.

Conclusions/Significance

The transplantation of anterior specified NPs may improve optic nerve injury through neuroprotection and differentiation into neuronal lineages. These NPs possibly provide a promising new therapeutic approach for traumatic optic nerve injuries and loss of RGCs caused by other diseases.     

Early remodelling of the extracellular matrix proteins tenascin‐C and phosphacan in retina and optic nerve of an experimental autoimmune glaucoma model

Glaucoma is characterized by the loss of retinal ganglion cells (RGCs) and optic nerve fibres. Previous studies noted fewer RGCs after immunization with ocular antigens at 28 days. It is known that changes in extracellular matrix (ECM) components conduct retina and optic nerve degeneration. Here, we focused on the remodelling of tenascin‐C and phosphacan/receptor protein tyrosine phosphatase β/ζ in an autoimmune glaucoma model. Rats were immunized with optic nerve homogenate (ONA) or S100B protein (S100). Controls received sodium chloride (Co). After 14 days, no changes in RGC number were noted in all groups. An increase in GFAP mRNA expression was observed in the S100 group, whereas no alterations were noted via immunohistochemistry in both groups. Extracellular matrix remodelling was analyzed after 3, 7, 14 and 28 days. Tenascin‐C and 473HD immunoreactivity in retinae and optic nerves was unaltered in both immunized groups at 3 days. At 7 days, tenascin‐C staining increased in both tissues in the ONA group. Also, in the optic nerves of the S100 group, an intense tenascin‐C staining could be shown. In the retina, an increased tenascin‐C expression was also observed in ONA animals via Western blot. 473HD immunoreactivity was elevated in the ONA group in both tissues and in the S100 optic nerves at 7 days. At 14 days, tenascin‐C and 473HD immunoreactivity was up‐regulated in the ONA retinae, whereas phosphacan expression was up‐regulated in both groups. We conclude that remodelling of tenascin‐C and phosphacan occurred shortly after immunization, already before RGC loss. We assume that both ECM molecules represent early indicators of neurodegeneration.     

Ocular neuroprotection by siRNA targeting caspase-2

Retinal ganglion cell (RGC) loss after optic nerve damage is a hallmark of certain human ophthalmic diseases including ischemic optic neuropathy (ION) and glaucoma. In a rat model of optic nerve transection, in which 80% of RGCs are eliminated within 14 days, caspase-2 was found to be expressed and cleaved (activated) predominantly in RGC. Inhibition of caspase-2 expression by a chemically modified synthetic short interfering ribonucleic acid (siRNA) delivered by intravitreal administration significantly enhanced RGC survival over a period of at least 30 days. This exogenously delivered siRNA could be found in RGC and other types of retinal cells, persisted inside the retina for at least 1 month and mediated sequence-specific RNA interference without inducing an interferon response. Our results indicate that RGC apoptosis induced by optic nerve injury involves activation of caspase-2, and that synthetic siRNAs designed to inhibit expression of caspase-2 represent potential neuroprotective agents for intervention in human diseases involving RGC loss.     

Effects of bone marrow stromal cell injection in an experimental glaucoma model

We investigated if bone marrow stromal cells (BMSCs) transplanted into the vitreous body of a glaucoma model eye could be integrated in the host retina and also whether they could rescue the retinal ganglion cells (RGCs) from death induced by the elevated intraocular pressure. Glaucoma was induced in the right eye of adult Wistar rats by ligating the episcleral veins. The GFP-expressing BMSCs (GFP-BMSCs) were injected into the vitreous body of both the control and the glaucomatous eyes. After transplantation, GFP-BMSCs were mostly present along with the inner limiting membrane and only a few cells were integrated into the ganglion cell layer. At 2 or 4 weeks after transplantation, GFP-BMSCs were observed to express various trophic factors. The BMSCs injected glaucoma model eyes showed less reduction in the number of RGCs compared to the glaucomatous eyes with PBS injection. This study suggests that BMSC transplantation may be worthy as a neuroprotective tool to treat glaucoma.     

Distribution of Mesenchymal Stem Cells and Effects on Neuronal Survival and Axon Regeneration after Optic Nerve Crush and Cell Therapy

Bone marrow-derived cells have been used in different animal models of neurological diseases. We investigated the therapeutic potential of mesenchymal stem cells (MSC) injected into the vitreous body in a model of optic nerve injury. Adult (3–5 months old) Lister Hooded rats underwent unilateral optic nerve crush followed by injection of MSC or the vehicle into the vitreous body. Before they were injected, MSC were labeled with a fluorescent dye or with superparamagnetic iron oxide nanoparticles, which allowed us to track the cells in vivo by magnetic resonance imaging. Sixteen and 28 days after injury, the survival of retinal ganglion cells was evaluated by assessing the number of Tuj1- or Brn3a-positive cells in flat-mounted retinas, and optic nerve regeneration was investigated after anterograde labeling of the optic axons with cholera toxin B conjugated to Alexa 488. Transplanted MSC remained in the vitreous body and were found in the eye for several weeks. Cell therapy significantly increased the number of Tuj1- and Brn3a-positive cells in the retina and the number of axons distal to the crush site at 16 and 28 days after optic nerve crush, although the RGC number decreased over time. MSC therapy was associated with an increase in the FGF-2 expression in the retinal ganglion cells layer, suggesting a beneficial outcome mediated by trophic factors. Interleukin-1β expression was also increased by MSC transplantation. In summary, MSC protected RGC and stimulated axon regeneration after optic nerve crush. The long period when the transplanted cells remained in the eye may account for the effect observed. However, further studies are needed to overcome eventually undesirable consequences of MSC transplantation and to potentiate the beneficial ones in order to sustain the neuroprotective effect overtime.     

A distinct effect of transient and sustained upregulation of cellular factor XIII in the goldfish retina and optic nerve on optic nerve regeneration

Unlike in mammals, fish retinal ganglion cells (RGCs) have a capacity to repair their axons even after optic nerve transection. In our previous study, we isolated a tissue type transglutaminase (TG) from axotomized goldfish retina. The levels of retinal TG (TG(R)) mRNA increased in RGCs 1-6weeks after nerve injury to promote optic nerve regeneration both in vitro and in vivo. In the present study, we screened other types of TG using specific FITC-labeled substrate peptides to elucidate the implications for optic nerve regeneration. This screening showed that the activity of only cellular coagulation factor XIII (cFXIII) was increased in goldfish optic nerves just after nerve injury. We therefore cloned a full-length cDNA clone of FXIII A subunit (FXIII-A) and studied temporal changes of FXIII-A expression in goldfish optic nerve and retina during regeneration. FXIII-A mRNA was initially detected at the crush site of the optic nerve 1h after injury; it was further observed in the optic nerve and achieved sustained long-term expression (1-40days after nerve injury). The cells producing FXIII-A were astrocytes/microglial cells in the optic nerve. By contrast, the expression of FXIII-A mRNA and protein was upregulated in RGCs for a shorter time (3-10days after nerve injury). Overexpression of FXIII-A in RGCs achieved by lipofection induced significant neurite outgrowth from unprimed retina, but not from primed retina with pretreatment of nerve injury. Addition of extracts of optic nerves with injury induced significant neurite outgrowth from primed retina, but not from unprimed retina without pretreatment of nerve injury. The transient increase of cFXIII in RGCs promotes neurite sprouting from injured RGCs, whereas the sustained increase of cFXIII in optic nerves facilitates neurite elongation from regrowing axons.     

骨髓间充质干细胞移植对脑梗死大鼠神经功能恢复的影响

目的:观察骨髓间充质干细胞(BMSC)移植对脑梗死大鼠神经功能恢复的影响,并对其相关机制进行探讨。方法:90只大鼠随机分为3组:假手术组、对照组、BMSC移植组,每组30只。对照组和BMSC移植组建立大鼠大脑中动脉阻塞(MCAO)模型,假手术组只需要分离大鼠颈部组织,而不造MCAO模型。BMSC移植组在MCAO模型术后1天经尾静脉注射1 mL/3×10~6 BMSC,对照组注射同剂量的生理盐水,于MCAO术后1 d、3 d、7 d、14 d、21 d、28 d、35 d、42 d、49 d分别对各组大鼠进行神经功能评分(mNSS),术后2个月对BMSC移植组及对照组大鼠脑组织进行免疫组化染色,检测MAP2、TUJ1、Ⅷ因子、GFAP的表达情况。结果:在治疗后的第7天至第35天,BMSC移植组mNSS均显著低于对照组(P0.05)。术后2个月,BMSC移植组MAP2、TUJ1、Ⅷ因子表达量显著高于对照组,而GFAP表达量显著低于于BMSC对照组(P0.01)。结论:BMSC移植可以促进脑梗死神经功能的恢复。